GMP PROTEIN (E. COLI) CONTRACT MANUFACTURING MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2026 - 2033)

GMP Protein (E. coli)  may or may not be manufactured using animal-free processes depending on the characteristics of the protein. Recombinant Protein is a protein encoded by a gene recombinant DNA that has been cloned in a system that supports the expression of the gene and translation of messenger RNA. Modification of the gene by recombinant DNA technology can lead to the expression of a mutant protein. Proteins co-expressed in bacteria will not possess post-translational modifications, e.g. phosphorylation or glycosylation. Some of the recombinant proteins which were produced and commercialized in medications are Humulin, Hematrope, Avonex, Kogenate, Pulmozyme and others.

Market Dynamics

Increasing launches of products in the market is expected to drive the growth of the global GMP protein (E. coli) contract manufacturing market over the forecast period. For instance, in June 2022, AMSBIO, a provider of quality life science research reagents and services, announced the launch of its Stem Fit Protein range of recombinant proteins for cell therapy applications. The Stem Fit Protein range includes recombinant proteins that play key roles in differentiating Embryonic Stem (ES) and induced Pluripotent Cells (iPS) in the pancreas, heart, kidney, blood, and immune cells. Moreover, in September 2021, Aviva Systems Biology, a company providing antibodies, immunoassay kits, and recombinant proteins for life science research, announced the launch of its new Protein on Demand semi-custom GMP grade recombinant protein portfolio for life scientists conducting basic research and preclinical studies. The Protein on Demand portfolio of over 300,000 proteins allows rapid access to small- to mid-scale production of customized proteins for research teams.

Key features of the study

• This report provides an in-depth analysis of the global GMP protein (E. coli) contract manufacturing market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global GMP protein (E. coli) contract manufacturing market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Merck & Co., Inc., Thermo Fisher Scientific Inc., Abcam plc, GenScript, Biomay AG, SOL GROUP, Proteintech Group, Inc., Nordmark Pharma GmbH, Sino Biological, Inc., Sino Biological, Inc., Abnova Corporation, Eurofins Scientific, Arcline Investment Management LP, Abgenex, Xpress Biologics, Avid Bioservices Inc, Bio-Techne, Northway Biotech, Aldevron, Institut Mérieux, PerkinElmer Inc., Creative BioMart, Profacgen, ProBioGen AG, 53Biologics, Leadgene Biomedical, Inc., Ajinomoto Bio-Pharma, FUJIFILM Diosynth Biotechnologies, Avioq, Inc, Biovian Oy, KBI Biopharma, GTP Bioways, QIAGEN, Suzhou Novoprotein Technology Co., Ltd., ACROBiosystems, Kactus, F. Hoffmann-La Roche Ltd., and Enzo Life Sciences, Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global GMP protein (E. coli) contract manufacturing market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global GMP protein (E. coli) contract manufacturing market.

Market Segmentation

• Global GMP Protein (E. coli) Contract Manufacturing Market, By Product Type
  • Cytokines
  • Growth Factors
  • Enzymes
    • DNA polymerase
    • Protease
    • Trypsin
    • Nuclease
      • Benzonase
      • Cas9 Nucleases
      • Others
    • IVT Enzymes
    • Others
  • Hormones
  • Antigens
  • Others
• Global GMP Protein (E. coli) Contract Manufacturing Market, By Application:
  • Gene Therapy
  • Cell Therapy
• Global GMP Protein (E. coli) Contract Manufacturing Market, By Method:
  • In-Vivo
  • Ex-Vivo
• Global GMP Protein (E. coli) Contract Manufacturing Market, By End User:
  • Biotechnology and Pharmaceutical Companies
  • Academic & Research Institutes
  • Contract Research Organizations
  • Others
• Global GMP Protein (E. coli) Contract Manufacturing Market, By Region:
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • Central Africa
    • North Africa
• Key Players
  • Merck & Co., Inc.,
  • Thermo Fisher Scientific Inc.,
  • Abcam plc,
  • GenScript,
  • Biomay AG
  • SOL GROUP
  • Proteintech Group, Inc.
  • Nordmark Pharma GmbH
  • Sino Biological, Inc.
  • Abnova Corporation
  • Eurofins Scientific
  • Arcline Investment Management LP
  • Abgenex
  • Xpress Biologics,
  • Avid Bioservices Inc
  • Bio-Techne,
  • Northway Biotech